14 citations
,
January 2003 in “Skin Research and Technology”
This study found that the scalp coverage scoring (SCS) method is a non-invasive and reproducible technique that effectively measures hair growth and loss dynamics in male subjects with androgenetic alopecia.
August 2025 in “American Journal of Clinical Dermatology”
This vodcast discusses various tools for assessing the severity of alopecia areata, emphasizing the importance of considering psychosocial impacts alongside physical symptoms.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinicalvalidation or approval for RU58841.
Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.
Some individuals do not respond to oral minoxidil for hair loss, despite it generally working by improving blood flow to hair follicles. Factors like metabolism, drug interactions, and individual variations in the drug's activation may influence its effectiveness.
1 mg of finasteride is commonly prescribed because it is more effective for a larger number of people compared to lower doses, despite only slightly reducing serum DHT more than 0.2 mg. Serum DHT and scalp DHT are different, and 1 mg is believed to reduce scalp DHT more effectively, contributing to better hair growth results.
The conversation discusses the effects of finasteride on hair loss and its potential neurological and sexual side effects. Users share personal experiences, with some reporting positive outcomes and others expressing concerns about cognitive function.
What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth?No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.
Are there any clinical studies supporting follistatin as a hair loss treatment?There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.